SMS Pharmaceuticals Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the certificate for the quarter ended March 31, 2026, demonstrating its adherence to dematerialization procedures and regulatory compliance standards.

Regulatory Compliance Filing

The company submitted the compliance certificate to both BSE Limited and National Stock Exchange of India Limited on April 7, 2026. The filing was made under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly compliance reporting for listed companies.

Registrar Confirmation

M/s. Aarthi Consultants Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on April 3, 2026. The registrar confirmed that all required actions were completed within the stipulated 15-day timeframe upon receipt of security certificates from depository participants for dematerialization purposes.

The registrar's certificate outlined specific compliance actions undertaken during the quarter:

• Securities comprised in dematerialized certificates are listed on appropriate stock exchanges
• Mutilation and cancellation of physical certificates forwarded by participants
• Substitution of depository name as registered owner in company records

Corporate Structure and Operations

SMS Pharmaceuticals Limited operates from its registered and corporate office located at Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5, Banjara Hills, Hyderabad. The company holds CIN L24239TG1987PLC008066 and maintains its pharmaceutical operations under the leadership of Company Secretary Thirumalesh Tumma, who signed the compliance filing.

Regulatory Framework

The quarterly compliance certificate represents part of the broader regulatory framework governing depositories and participants in India's securities market. SEBI regulations require listed companies to maintain transparency in their dematerialization processes and ensure proper handling of security certificates through authorized registrars and transfer agents.

Aarthi Consultants Private Limited, holding SEBI Registration Number INR000000379 as Category I Registrars & Share Transfer Agents, continues to serve as the company's compliance partner for regulatory filings and share transfer operations.

SMS Pharmaceuticals Limited has informed stock exchanges about receiving an income tax demand notice worth Rs 7.19 crores for Assessment Year 2018-19. The pharmaceutical company disclosed this development under Regulation 30 of the SEBI (LODR) Regulations, 2015.

Income Tax Demand Details

The company received the demand notice on 31st March, 2026, from the Faceless Assessment Unit of the Income Tax Department. The notice was issued under Section 156 of the Income Tax Act, 1961, and dated 30th March 2026.

Assessment Order Specifics

The Assessment Unit passed an assessment order under Section 147 read with Section 144B of the Income Tax Act, 1961. The order involved two key components:

• Addition of income to the company's declared income
• Disallowance of deduction claimed under Section 35 of the Act

Additionally, penalty proceedings under Section 270A have been initiated separately for under reporting of income.

Company's Response and Impact

SMS Pharmaceuticals stated that there will be no material impact at this stage on the financial, operational, and other activities of the company. The management emphasized that the company is currently reviewing the order and evaluating the next steps to be taken before the appropriate forum against the said order.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015. The company also complied with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/25 dated February 25, 2025, regarding disclosure of communication from regulatory authorities.

The company confirmed that the information provided is in compliance with Regulation 30(13) of the SEBI (LODR) Regulations and is true, correct, and complete to the best of their knowledge and belief.